EGFR and non-small cell lung carcinoma: This study estimated the costs associated with expanding access to PD1/PD-L1 inhibitors as first-line monotherapy for individuals aged 40–74 years with EGFR-wildtype PD-L1 TPS ≥ 50% unresectable or metastatic NSCLC.